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Chloroquine is still a first-line antimalarial drug in uncomplicated falciparum malaria. Increasing 
resistance to chloroquine has been reported in many parts of Nigeria. Clinical and parasitological 
responses and classes of resistance to chloroquine in falciparum malaria in five communities in Delta 
region, southern Nigeria were assessed. Chloroquine was administered to 218 patients with 
uncomplicated P. falciparum malaria. The levels of parasitemia, clinical response and classes of 
resistance were monitored for 7 days. High levels of therapeutic failures of chloroquine in P. falciparum 
malaria were recorded in the region. The frequencies of clinical and parasitological failure of 
chloroquine were 25.7% and 55%, respectively. These frequencies were significantly lower in children 
below 5 years than older people. R2 and R3 resistance occurred in 37.2% and 17.4% of the patients, 
respectively.  The therapeutic failure of chloroquine was not gender dependent. We conclude that 
chloroquine is still effective in the treatment of uncomplicated P. falciparum malaria in some 
communities in Delta region of Nigeria. However, resistance to chloroquine is likely. These results may 
be used as an important indicator of the significant level of therapeutic failure of uncomplicated P. 
falciparum malaria to chloroquine in Nigeria.  
 





Malaria is the second leading health problem (the first 
being HIV/AIDS) in sub-Saharan Africa accounting for 
over 1 million deaths yearly in the region (Rathod et al., 
1997). These deaths are primarily among children under 
5 years of age and pregnant women (Phillips, 2001). The 
disease can increase the risk of major problems including 
anaemia, premature births, still-births, abortion and low 
birth weight. Health and socio-economic problems 
caused by malaria in sub-Saharan Africa are enormous, 
and the development and spread of malaria parasite 
resistance to drugs have led to global recognition and 
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Malaria in Africa is mainly due to a blood parasite, 
Plasmodium falciparum. Chloroquine, which was 
introduced in the 1940s, and for many decades served as 
a cheap and reliable drug, is becoming ineffective against 
P. falciparum in most tropical areas (Rathod et al., 1997; 
Warhurst, 2001). Resistance to chloroquine developed in 
Southeast Asia and South America at the end of the 
1950s and in Africa by the late 1970s (Warhurst, 2001). 
Since the emergence of chloroquine resistant strains of 
P. falciparum, the rate of resistance has been increasing 
and limiting adequate treatment of malaria (Peters, 1998;  
Neequaye et al., 1986). Despite the growing resistance of 
P. falciparum, chloroquine remains the first line 
antimalarial drug in Nigeria and many other African 
countries mainly on account of cost and effectiveness in 
uncomplicated cases of malaria. Resistance to 





within the last decade in different parts of Nigeria (Molta, 
1995; Umotong et al., 1991; Salako et al., 1990; 
Sowunmi et al., 1990; Sowunmi and Salako, 1992). In the 
study carried out in northeastern Nigeria, for example, 
most strains of P. falciparum were found to be fully 
sensitive to chloroquine (Molta, 1995). However, strains 
with reduced sensitivity and resistant strains have 
emerged with parasitological failure increasing from 
18.7% in 1988 to 24.5% in 1995 (Molta, 1995). 
Consistently high resistance to chloroquine by malaria 
parasite has also been reported in southeastern Nigeria 
(Umotong et al., 1991). 
The goal of chemotherapy in malaria therapy is often 
to effect a clinical cure or parasitological clearance or to 
limit the development of drug resistance. Resistance to 
chloroquine is often manifested in subtle ways which are 
only apparent when the treatment is accompanied by 
detailed follow-up. Accurate and effective surveillance 
systems for monitoring antimalarial drug efficacy have 
been recognized as an essential basis for decisions on 
the use of drugs (Malaria Foundation International, 1998). 
Surveillance is often carried out at different levels of 
sophistication, from basic drug efficacy tests through to 
more detailed in vitro characterization of drug resistant 
parasite strains and clinical information. The World 
Health Organization has recognized that malaria 
treatment failure rate of 5% to 14% signals an alert phase 
in malaria monitoring while failure rates of 15% to 24% 
signals the need for action (WHO, 2002a). Among other 
factors, reports of chloroquine resistant P. falciparum 
treatment failure rate of up to 53.6% in southeastern 
Nigeria (Umotong et al., 1991) and up to 37% in 
southwestern part of Nigeria (Salako et al., 1990; 
Sowunmi et al., 1990) with a drop to 15% in 1992 
(Sowunmi and Salako, 1992) justifies the need for 
continuous monitoring of resistance to chloroquine. 
The main purpose of this study was to ascertain the 
therapeutic efficacy of treatment of uncomplicated P. 
falciparum malaria with chloroquine in the Delta region of 
Nigeria. Specifically, the parasitological and clinical 
responses of P. falciparum to chloroquine and the 
classes of resistance are evaluated. The data obtained 
from this study would provide useful information for future 
management of uncomplicated P. falciparum malaria in 







This study was carried out in a government-owned 
Central Hospital, Warri which is a 300-bed tertiary health 
care facility. It involved patients drawn from five 
communities in Delta State, Southern Nigeria namely, 
Agbarho, Aladja, Effurun, Ekpan and Enerhen with a 
population of over 1 million inhabitants. These 
communities are located in malaria endemic oil  rich  area  




of Delta State and were selected because of their 
proximity to the study site. Apart from Agharho (a village 
whose inhabitants are mainly farmers), the communities 
are urban communities whose inhabitants are mainly 
petty traders, civil servants and workers in the oil 
industry. They are served by the Central Hospital, Warri 
and Shell Petroleum Hospital, Warri as well as private 
clinics, herbal homes, pharmaceutical stores and patent 
medicine stores. Like other parts of southern Nigeria, the 
climate is equatorial, with 2 seasons: rainy season from 
May to October and dry season from November to April. 
 
 
Patients and study protocol 
 
After ethical approval from the Delta State Ministry of 
Health, Asaba, 500 males and females patients (age: 6 
months and above) with history of fever (axillary 
temperature ≥ 37.5oC) in the last 48 h before attending 
the hospital (Central Hospital, Warri) were clinically 
examined and screened for malaria parasites using both 
clinical examination and laboratory data. Of the 500 
patients, 218 patients (age range, 6 months to 48 years) 
met the criteria for inclusion in the data analysed. These 
patients were selected from the 5 communities using 
simple random sampling as earlier described (WHO, 
1992). The sample was evenly distributed among the 
communities selected and the sample size was 
satisfactory in respect of the calculated sample size of 
patients based on the population of the communities at 
95% confidence interval, 5% precision, and expected 
proportion of treatment failure of 5% – 14 % (WHO, 
2002a).  
The criteria for inclusion in the study included the 
presence of P. falciparum malaria as determined by 
clinical examination and laboratory data (parasite count; 
2,000 to 200,000 per µl blood) and informed consent. 
Other criteria for inclusion were:  (1) ability to be followed 
up for 7 days, (2) presence of febrile conditions caused 
by P. falciparum malaria, (3) absence of general danger 
signs or signs of severe and complicated P. falciparum 
malaria, and (4) the fact that the patient has not taken 
any antimalarial drug within 2 week period preceding the 
study.  However, patients with clinical symptoms 
compatible with severe or complicated malaria or with 
any other symptoms or signs of non-malarial etiology 
were excluded from the study and referred to appropriate 
health services. Also excluded were patients with 
repeated vomiting, diarrhoea, malnutrition, pregnancy, 
difficulty in complying with drug treatment, and inability to 
comply with the stipulated follow-up visits on days 3 and 
7.  
The 218 patients (113 males and 105 females 
including 78 children below 5 years) were routinely 
treated with chloroquine orally: adults were treated with 
600 mg chloroquine base stat and 24 h later followed by 
300 mg next day; children received 10 mg/kg stat and  24  




                     Table 1. Age and sex distribution of patients with P. falciparum malaria treated with chloroquine. 
 
Age Male (%)a Female (%)a Total (%) 
6 months to < 5 years 40 (18.3) 38 (17.4) 78 (35.8) 
5 – 48 years 73 (33.5) 67 (30.7) 130 (64.2) 
Total 113 (51.8) 105 (48.2) 218 (100) 
          aχ2 = 0.015, df = 1, p = 0.903 
 
 
h later, then 5 mg/kg next day, as appropriate. Each 
patient was also given appropriate doses of paracetamol 
and multivitamin orally. The qualities of drugs 
administered were evaluated and found to have met the 
British Pharmacopoeia (BP, 1998) standard before they 
were used for this study. All patients were treated as 
outpatients and were appropriately followed up for 7 days 
with clinical and laboratory examinations at 3 h, day 3 
and day 7 following the start of treatment with 
chloroquine. Blood samples were also obtained from the 
patients during the follow-up days and malaria parasite 
levels determined using standard methods (Ejov et al., 
1999; Hombhanje, 1997). 
 
 
Clinical and parasitological responses to chloroquine 
 
Clinical failure was considered to have occurred if a 
patient had fever or history of fever (axillary temperature 
≥ 37.5oC) by day 7 with parasitemia detected in blood or 
assessed to have been ill due to no other cause than 
malaria. Parasitological failure was considered to have 
occurred if parasite count in blood was ≥ 25% of count on 
day 0 by day 7.  
 
 
Level of resistance to chloroquine 
 
We adopted the 7-day WHO in vivo test protocol in 
determining the class of resistance to chloroquine (Bruce, 
1986). Patients with marked reduction of parasitemia 
(parasite count reduced by more than 75%) at 48 h but 
failed to clear parasites by day 7 were considered to be 
R2 resistant to chloroquine. Patients whose parasitemia 
did not fall by more than 75% within 48 h or occasionally 
increased by day 7 were considered to be R3 resistant to 
chloroquine. R1 resistance (clearance of asexual 
parasitemia on or after day 7 followed by recrudescence) 
was not determined because the patients were only 
monitored for 7 days and it is not possible to determine 
recrudescence in areas of intense malaria transmission 
as in the communities studied.  
 
 
Statistical Analysis of data 
 
The data obtained were categorized based on sex and 
age and reported as frequencies. Data were compared 
with Chi square test or Fisher’s Exact test, using a 
computer software, Instat (GraphPad Inc., USA). 
Probability (p) was considered at 95% confidence 
interval, and 2 – tailed p-values less than or equal to 0.05 
were accepted to imply significant differences between 





Age and sex distribution of patients 
 
The age and sex distribution of the 218 patients who fully 
participated in this study are given in Table 1. This 
number excluded those who either defaulted or withdrew 
from the study on account of convenience. There was no 
significant difference between the number of males and 
females, and the number of children below 5 years when 




Clinical and parasitological responses to chloroquine 
 
The clinical and parasitological responses to chloroquine 
are shown in Table 2.  Chloroquine produced a clinical 
success of 74.3% in the eradication of malaria parasites 
in the patients but parasitological success was only 
achieved in 45% of the patients. The proportion of 
patients with clinical failure or parasitological failure were 
significantly higher in patients from 5 to 48 years old than 
patients below 5 years (p ≤ 0.001). Furthermore, the 
proportion of patients from 5 to 48 years old with clinical 
failure was more than twice the proportion of patients 
below 5 years with clinical failure. Also, the proportion of 
patients from 5 to 48 years years old with parasitological 
failure was nearly doubled the proportion of patients 
below 5 years with parasitological failure. Gender had no 
significant effect on either the clinical response or 
parasitological response to chloroquine (p > 0.05).  
 
 
Level of resistance to chloroquine 
 
Class II (R2) and class III (R3) types of resistance were 
found to have occurred in 81 (37.2%) and 38 (17.4%) of 
the patients, respectively. We found no significant 
differences in the levels of resistance in males when 
compared to those of the females (p > 0.05). 




                Table 2. Clinical and parasitological response of chloroquine in patients with P. falciparum malaria.  
 
Age (years) Sex  
Response < 5 (%) 
n=78 








Clinical failure 10 (12.8)b 46 (32.9)b 28 (24.8) 28 (26.7) 56 (25.7) 
Parasitological failure 27 (34.6)c 93 (66.4)c 62 (54.9) 58 (55.2) 120 (55.0) 






Drug resistance in malaria is the ability of the parasite 
strains to survive and/or multiply despite administration 
and absorption of a drug given in doses equal to or 
higher than those usually recommended but within the 
limits of tolerance of the subject (Bruce, 1986). The World 
Health Organization (WHO) categorized resistance in 
malaria as S (sensitive), R1, R2 and R3 based on in vivo 
test (Bruce, 1986). This test was replaced in 1996 by 
WHO with the Therapeutic Efficacy Test based on clinical 
and parasitological criteria - a pragmatic test for National 
Malaria Control Programme (WHO, 1996). We have used 
these two approaches to evaluate the effectiveness of 
chloroquine in the five communities studied. Our results 
have shown that chloroquine is still effective in the 
treatment of uncompicated P. falciparum malaria in the 
communities despite the high prevalence of chloroquine-
resistant malaria in the region. This is evident in the 
clinical success of chloroquine in 74.3% of the patients. 
However, parasitemia was still evident in 45% of the 
patients by the 7th day after the first dose of chloroquine 
was administered, indicating resistance to chloroquine. 
We recognise that a mixed population of malaria parasite 
strains (susceptible and resistant) can be present in the 
blood of the patients. In this situation, the susceptible 
strains would be killed by the chloroquine in the early part 
of the treatment, making way for more resistant and 
virulent strains to multiply later (Wernsdorfer et al., 1995).  
Children under the age of 5 years are known to be the 
most susceptible group to malaria mortality (WHO, 
2002b). The severity and prevalence of malaria are also 
higher in this age group than older children and adults 
(May et al., 1999; Mockenhaupt et al., 2000). 
Furthermore, at equal dosages per body weight, plasma 
chloroquine concentrations are lower in children below 5 
years of age than older children and adults (Maitland et 
al., 1997). These indications would suggest that the 
therapeutic failure of chloroquine in malaria treatment is 
likely to be higher in children younger than 5 years than 
older people. Conversely, our results indicate that 
children younger than 5 years had much lower 
therapeutic failure rates than older people. The reason for 
this is unclear. Earlier report indicates that mixed species 
infections of malaria parasites are higher in children 
below 5 years (Mockenhaupt et al., 2000) than older 
people. Malaria infections with parasite strains other than 
P. falciparum have been suggested to act as natural 
vaccines preventing severe manifestations of P. 
falciparum infections (Williams et al., 1996). If this 
suggestion holds, clearance of P. falciparum malaria in 
the patients below 5 years of age could be enhanced, as 
none of them had severe malaria. Furthermore, long-term 
exposure to chloroquine, particularly by presumptive 
chloroquine treatment or prophylaxis, are prerequisites 
for the emergence of chloroquine resistance 
(Mockenhaupt et al., 2000). This situation is less likely to 
occur in children below the age of 5 years than older 
people. The efficacy of chloroquine is thus more likely to 
be lower in people older than 5 years than those below 5 
years of age. Greater awareness on the need for early 
and proper treatment in chlidren below 5 years of age 
may also be a contributing factor. Gender appears not to 
play a role in therapeutic efficacy of chloroquine as we 
found no significant difference between the frequency of 
therapeutic failures in males as compared to females. 
Increasing resistance of P. falciparum malaria to 
chloroquine has earlier been reported in some parts of 
Nigeria (Umotong et al., 1991). Survellance network in 
the country from mid-1987 to 1990 revealed that 
chloroquine resistant P. falciparum (CRPF) was 
widespread (Ekanem, 1997). In the northern part of the 
country, parasitological failures increased from 18.7% in 
1988 to 24.5% in 1995 (Molta, 1995). From 1987 to 1997, 
resistance ranging from 33% to 72% was also reported in 
the southern part of the country (Ekanem, 1997). 
Although the parasitological failure found in our study is 
similar to the 53.6% found in Calabar, southern Nigeria in 
1991 (Umotong et al., 1991), stability of resistance to 
chloroquine in the area studied cannot be inferred 
because the two areas (Calabar and Delta region) are  in 
different locations. Clinical failure of 25.7% recorded in 
this study is also similar to the 22% reported in Ibadan, 
southern Nigeria in 1997 (Ekanem, 1997; Oduola, 1997). 
The frequencies of clinical and parasitological failures 
following chloroquine treatment are indicative of the 
continuous emergence of chloroquine resistance strains 
of P. falciparum in the communities studied and most 
likely in other parts of the country.  These frequencies are 
at unacceptable levels having exceeded the 15 – 24% set 
by WHO (2002a) as action phase. Thus, the need for 
action  to  be  taken   to   address   the   problem   in   the 




communities and other parts of the country has become 
very urgent. 
Based on WHO earlier categorisation of resistance to 
antimalarial drugs (class I, R1; class II, R2 and class III, 
R3), our results have demonstrated high proportions of 
R2 (37.2%) and R3 (17.4%) resistance in the 
communities studied. The R3 resistance was similar to 
that reported in 1991 in Calabar (Umotong et al., 1991). 
Studies have shown that R3 resistance to chloroquine is 
not present in some areas in Congo (Carme et al., 1998) 
and Madagascar (Raharimalala et al., 1995) but present 
at a very low level in Coté d'Ivoire (Henry et al., 1998). R3 
resistance in this study is lower than the 23% reported in 
Zimbabwe (Mohamva et al., 1996) and the 22% reported 
in Port Moresby, Papua New Guinea (Hombhanje, 1997). 
However, the R2 resistance in our results is much higher 
than the 10% reported in Zimbabwe (Mohamva et al., 
1996) and the 4% reported in Papua New Guinea 
(Hombhanje, 1997). High, rather than low, doses of 
chloroquine is believed to induce R3 resistance to 
chlroquine (Henry et al., 1998). 
The mechanism of resistance to chloroquine in the 
communities studied is not clear, since the mechanism of 
resistance to antimalarial drugs is still debatable 
(Wellems et al., 1990; Rathod et al., 1997; Phillips, 2001).  
However, resistance to chloroquine has been reported to 
be due to reduced uptake of the drug by the infected 
erythrocyte and presumably reflects a reduction in the 
accumulation of the drug in the parasite’s lysosome 
(Phillips, 2001; Warhurst, 2001). Association between 
chloroquine resistance and mutations in an mdr-like gene 
(pfmdr-1) has been reported (Warhurst, 2001). There is 
evidence to suggest that a mutation in pfcrt is required to 
confer a basic level of resistance before mutations in 
pfmdr-1 can have an effect; the basis for the suggested 
use of a rapid and sensitive test to detect pfcrt T76 in 
blood samples to ascertain the effectiveness of 
chloroquine (Warhurst, 2001; Reed et al., 2000). A 
number of factors have been identified as playing a role 
in the emergence of resistance to chloroquine. These 
include poor compliance to drug therapy, host immunity, 
use of sub-therapeutic doses, mutation and frequency of 
re-infection (Hombhanje, 1997; Phillips, 2001; 
Werndorfer, 1991). 
Treatment of uncomplicated malaria in the Niger-Delta 
region (where this study was carried out) is frequently 
based on the fact that as long as chloroquine is effective 
enough, there is very little incentive for basing its use on 
reliable diagnostic confirmation. As in the communities 
studied, resistance to antimalarial drugs is proving to be a 
challenging problem in malaria control in most parts of 
the world. A fundamental aspect of drug usage 
recommendations is the impact of resistance on morbidity 
and mortality and hence the impact of the timing and 
nature of a policy decision on the health of the people in 
the community studied and the rest of the country. The 





has been established as a measure to improve treatment 
efficacy, delay the emergence of drug resistance, and 
reduce the prevalence of gametocyte carriage which 
could, in turn, reduce transmission of malaria parasites 
(WHO, 2001a,b). Cost considerations in many parts of 
the country would support the use of empirical treatment 
with chloroquine or an alternative first-line drug, such as 
sulfadoxine-pyrimethamine (Warhurst, 2001), in patients 
with uncomplicated malaria. In the case of more 
expensive drug regimens, the cost would have to be 
balanced against the potential savings in the cost of 
treatment. Reliable, microscopy-based diagnosis should 
be mandatory in view of the financial implications when 
much more expensive alternative drugs need to be used 





Chloroquine is still effective in the treatment of most 
cases of uncomplicated P. falciparum malaria in some 
communities in Delta State, Nigeria. However, in many 
cases of uncomplicated P. falciparum malaria, resistance 
to chloroquine is likely and intervention with alternative 
antimalarial drugs may be required for complete 
clearance of parasitemia in the patients. Despite the 
limited communities in which this study was carried out, 
our results may be used as an important indicator of the 
significant level of therapeutic failure of uncomplicated P. 
falciparum malaria to chloroquine in Nigeria. Additional 
drug efficacy assessment throughout the country is 
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